Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps: can sound waves tweak your thinking?

NCT ID NCT07389447

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how focused ultrasound (sound waves) aimed at the cerebellum changes brain activity and thinking in 20 healthy adults aged 18 to 40. Participants do thinking tasks after real or fake ultrasound. The goal is to learn how the cerebellum affects brain function, not to treat any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Exclusion Criteria: * Participants must not have claustrophobia or anxiety regarding MRI scan. * Participants must not have current or planned pregnancy. * Participants must not have history of neurological or psychiatric disorder. * Participants must not have predisposition for fainting spells (syncope). * Participants must not have implanted material (e.g., pacemaker, neurostimulator, medication infusion device, cochlear implants). * Participants must not have medical patch that cannot or may not be taken off (e.g., nicotine patch). * Participants must not be currently taking psychoactive medication, or must have stopped taking such medication for at least 2 weeks before starting experiment (excluding contraception). * Participants must not have skin disease on or close to the scalp. * Participants must not have direct relatives (parents, siblings, children) with epilepsy, convulsion, or seizure. * Participants must abstain from the use of any recreational drugs in the 48-hour period prior to taking part in the experiment. * Participants must not consume more than 4 alcoholic units within the 24-hour period before participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic enteropathy associated with SLCO2A1 gene cognitive disorder injury stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGENCY CCAS Cognition Stroke Trauma Verbal memory

Contacts and locations

Locations

  • Precision Medical Imaging, QMC

    Nottingham, Nottinghamshire, NG7 2UH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.